Results about: patients
Researchers at IDIBAPS and IRB Barcelona have described in Cancer Research, that the longer the time from the onset of the tumour to the development of metastasis is, the more aggressive this cancer becomes.
Research centres of excellence in Barcelona offer PhD fellowships to medical doctors.
Called PhD4MD, the programme allows medical doctors to carry out a three-year doctoral thesis on cancer, rare disease or neurodegenerative conditions.
It was the first time that Group Leader and ICREA researcher Maria Macias organised a Barcelona BioMed Conference, in collaboration with the BBVA Foundation, held on 28-30 November 2016. When asked about the experience, she highlights that having been able to draw together experts from very diverse research fields and backgrounds was “extremely fulfilling” for her. The conference programme covered areas spanning genomics to systems biology, cellular structural biology, big data, and patients-focussed approaches.
A study at IRB Barcelona has identified the cells responsible for initiating and promoting metastasis in several types of human tumours.
Their results show that the protein CD36, which absorbs fat from the cell membrane, is an essential factor that determines whether tumour cells become metastatic.
In the absence of CD36, the human tumours analysed did not develop metastasis. In addition, the inhibition of this protein also dramatically reduced the size of existing metastases.
Mice given a high-fat diet developed the most aggressive metastases. The study reports that the metastatic process is enhanced by fat intake.
IRB Barcelona will co-develop antibodies against CD36 with the potential to treat patients.
As of November, Núria López-Bigas, winner of the 2016 Banco Sabadell Foundation Prize for Biomedical Research, will join IRB Barcelona to continue her research on cancer using computational biology.
The Institute has also recruited Croatian scientist Fran Supek, who will launch his laboratory in 2017.
The biotech will set aside this injection of capital –led by Caixa Capital Risc- to complete the preclinical phase in order to start Human Phase I trials of its compound to the treatment of Cognitive Impairment Associated with Schizophrenia. The drug is one of the few under development worldwide to halt the progression and reverse the symptoms of this condition.
The drug is a first-in-class for the treatment of Cognitive Impairment Associated with Schizophrenia (CIAS). The compound has been developed using their proprietary IPROTech, a cutting-edge platform the fast and cost-effectively obtaining of innovative drugs.
Iproteos, settled at the Parc Cientific de Barcelona, is a spin-off created in 2011 by two Catalan leading scientists in the field of therapeutic peptides, Teresa Tarragó and Ernest Giralt, based on the technology transfer from IRB Barcelona and the University of Barcelona.
Centres of excellence in biomedical research in Barcelona offer five fellowships as part of the new edition of the predoctoral programme in biomedicine for physicians, PhD4MD.
The initiative allows physicians to embark on a three-year research project on topics such as cancer, chronic obstructive pulmonary disease, fertility, and AIDS vaccines.
Thanks to the collaboration among research centres, the studies will address two distinct facets of biomedicine: basic molecular research and more applied clinical work.